COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 12 of 18 for:    ibudilast

Ibudilast for the Treatment of Alcohol Use Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03594435
Recruitment Status : Recruiting
First Posted : July 20, 2018
Last Update Posted : October 10, 2019
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Information provided by (Responsible Party):
Lara Ray, PhD, University of California, Los Angeles

Brief Summary:
This study is a double-blind, placebo-controlled randomized clinical trial of IBUD (50mg BID) for the treatment of Alcohol Use Disorder (AUD). Eligible participants will undergo a 12-week medication treatment period and 5 in-person visits over 16 weeks.

Condition or disease Intervention/treatment Phase
Alcohol Use Disorder Drug: Ibudilast Drug: Placebo oral capsule Phase 2

Detailed Description:
The study design consists of a 12-week, double-blind, placebo-controlled randomized clinical trial of IBUD (50mg BID) for the treatment of Alcohol Use Disorder (AUD). The investigators will randomize 132 treatment-seekers with current AUD over the course of 4 years. As a behavioral support platform, all participants will complete the NIAAA-developed and computer-delivered program "Take Control" during the study. Participants will complete telephone screening, followed by in-person eligibility assessment, a physical exam for medical eligibility, randomization to study medication or matched placebo, and in-person follow-up visits at 4, 8, and 12 weeks of treatment. TLFB assessment of drinking outcomes will also occur by telephone on weeks 2, 6, and 10. A final safety check visit will occur on week 16, consisting of repeated clinical labs and ECG.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 132 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Two-Arm, Randomized, Double-Blind, Placebo-Controlled
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized Controlled Clinical Trial of the Neuroimmune Modulator Ibudilast for the Treatment of Alcohol Use Disorder
Actual Study Start Date : October 1, 2018
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : September 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Alcohol

Arm Intervention/treatment
Experimental: Ibudilast
10mg delayed-release capsules, target dose 50mg BID (5 x 10mg capsules twice daily) for 12 weeks
Drug: Ibudilast
targets neurotrophin signaling and neuroimmune function
Other Names:
  • Pinatos
  • MN-166

Placebo Comparator: Placebo Oral Capsule
matched to experimental drug
Drug: Placebo oral capsule
matched to active drug, ibudilast
Other Name: Sugar Pill

Primary Outcome Measures :
  1. Percent heavy drinking days [ Time Frame: 12 week-treatment period ]
    Heavy drinking days defined as 5+ drinks for men and 4+ for women

Secondary Outcome Measures :
  1. Drinks per day [ Time Frame: 12-week treatment period ]
    secondary alcohol consumption endpoint

  2. Drinks per drinking day [ Time Frame: 12-week treatment period ]
    secondary alcohol consumption endpoint

  3. Percent days abstinent [ Time Frame: 12-week treatment period ]
    secondary alcohol consumption endpoint

  4. Percent subjects with no heavy drinking days [ Time Frame: 12-week treatment period ]
    secondary alcohol consumption endpoint

  5. Percent subjects abstinent [ Time Frame: 12-week treatment period ]
    secondary alcohol consumption endpoint

Other Outcome Measures:
  1. Depressive Symptomatology [ Time Frame: 12-week treatment period ]
    Responses from Beck Depression Inventory II (BDI-II) will be used to test this outcome

  2. Neuroinflammation [ Time Frame: 12-week treatment period ]
    Blood levels of proinflammatory markers

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Be between the ages of 18 and 65
  2. Meet current (i.e., past 12 months) DSM-5 diagnostic criteria for alcohol use disorder moderate or severe
  3. Be treatment-seeking for AUD
  4. Report drinking at least 28 drinks per week if male (21 drinks per week if female) in the 28 days prior to consent

Exclusion Criteria:

  1. Have a current (last 12 months) DSM-5 diagnosis of substance use disorder for any psychoactive substances other than alcohol and nicotine
  2. Have a lifetime DSM-5 diagnosis of schizophrenia, bipolar disorder, or any psychotic disorder
  3. Have a positive urine screen for narcotics, amphetamines, or sedative hypnotics;
  4. Have clinically significant alcohol withdrawal symptoms as indicated by a score ≥ 10 on the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-R)
  5. Be pregnant, nursing, or planning to become pregnant while taking part in the study; and must agree to one of the following methods of birth control (if female), unless she or partner are surgically sterile:

    • Oral contraceptives
    • Contraceptive sponge
    • Patch
    • Double barrier
    • Intrauterine contraceptive device
    • Etonogestrel implant
    • Medroxyprogesterone acetate contraceptive injection
    • Complete abstinence from sexual intercourse
    • Hormonal vaginal contraceptive ring
  6. Have a medical condition that may interfere with safe study participation (e.g., unstable cardiac, renal, or liver disease, uncontrolled hypertension or diabetes)
  7. Have AST, ALT, or GGT ≥ 3 times upper normal limit
  8. Have attempted suicide in the past 3 years and/or have had serious suicidal intention or plan in the past year
  9. Currently be on prescription medication that contraindicates use of IBUD, including alpha or beta agonists, theophylline, or other sympathomimetic
  10. Currently be on any medications for AUD or any psychotropic medications (e.g., psychostimulants and benzodiazepines) with the exception of stable antidepressants (stable dose for ≥4 weeks)
  11. Have any other circumstances that, in the opinion of the investigators, compromises participant safety.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03594435

Layout table for location contacts
Contact: Jessica Jenkins, MS 310-206-6756

Layout table for location information
United States, California
UCLA Addictions Laboratory Recruiting
Los Angeles, California, United States, 90095
Contact: Jessica Jenkins, MA    310-206-6756   
Principal Investigator: Lara Ray, PhD         
Sub-Investigator: Karen Miotto, MD         
Sub-Investigator: Gang Li, PhD         
Sub-Investigator: Michael Irwin, MD         
Sub-Investigator: Steven Shoptaw, PhD         
Sponsors and Collaborators
University of California, Los Angeles
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Layout table for investigator information
Principal Investigator: Lara A. Ray, PhD University of California, Los Angeles
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Lara Ray, PhD, Professor, University of California, Los Angeles Identifier: NCT03594435    
Other Study ID Numbers: 18-000963
R01AA026190 ( U.S. NIH Grant/Contract )
First Posted: July 20, 2018    Key Record Dates
Last Update Posted: October 10, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Lara Ray, PhD, University of California, Los Angeles:
ibudilast, treatment, medication development
Additional relevant MeSH terms:
Layout table for MeSH terms
Alcohol Drinking
Drinking Behavior
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Vasodilator Agents